Lv7
6095 积分 2021-06-29 加入
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatin in patients with HER2-negative BC and HRD –long-term survival of the GeparOLA study
4天前
已完结
HER2 testing: evolution and update for a companion diagnostic assay
4天前
已完结
Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis
5天前
已完结
Phosphoinositide kinases in cancer: from molecular mechanisms to therapeutic opportunities
5天前
已完结
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
1个月前
已完结
Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care
1个月前
已完结
Impact of loss of HER2 positivity following neoadjuvant therapy in HER2 positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis
1个月前
已完结
Post-Progression treatment options after CDK4/6 inhibitors in hormone Receptor-Positive HER2-Negative metastatic breast cancer
1个月前
已完结
Final Survival Results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy – PENELOPE-B
1个月前
已完结
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer
3个月前
已完结
皖公网安备34019202002308
